Comparative Pharmacology
Head-to-head clinical analysis: CORT DOME versus LUXIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORT DOME versus LUXIQ.
CORT-DOME vs LUXIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses, and inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Hydrocortisone (Cort-Dome) typical adult dose: 100 mg intravenously or intramuscularly as a loading dose, followed by 50-100 mg intravenously every 6 hours for stress dosing; for replacement therapy: oral 20-30 mg daily in divided doses. Topical: apply sparingly to affected area 1-4 times daily.
Topical: Apply a thin film to affected areas of the scalp twice daily (morning and evening) for 2 weeks; do not exceed 50 g per week.
None Documented
None Documented
Plasma half-life is approximately 1-2 hours; biological half-life (duration of adrenal suppression) is 18-36 hours.
Terminal half-life: 3-5 hours; in renal impairment may extend to 8 hours.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 40-60% of elimination; less than 5% excreted unchanged in urine; biliary/fecal elimination is minor (<5%).
Renal: 30% unchanged; biliary/fecal: 70% as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid